IPCA Laboratories Ltd.: Fasting trials

The registry lists 12 Fasting studies with IPCA Laboratories Ltd. as lead sponsor. 0 are open to participants now and 0 have results posted.

Phase 1 12(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Bioequivalence Study of Metoprolol Succinate Extended Release Tablets 200 mg Under Fasting ConditionsCompletedNCT01884896Phase 1
• Bioequivalence Study of Metoprolol Succinate Extended Release Tablets 50 mgCompletedNCT01884857Phase 1
• Bioequivalence Study of Lisinopril and Hydrochlorothiazide Tablets (20+25) mg Under Fasting ConditionsCompletedNCT01831700Phase 1
• Bioequivalence Study of Etodolac Extended Release Tablets USP 600mg Under Fed ConditionCompletedNCT01831687Phase 1
• Bioequivalence Study of Metformin Hydrochloride Extended-Release Tablets USP 750 mg Under Fed ConditionCompletedNCT01831674Phase 1
• Bioequivalence Study of Metformin Hydrochloride Extended-Release Tablets USP 750 mg Under Fasting ConditionCompletedNCT01831661Phase 1
• Bioequivalence Study of Etodolac Extended Release Tablets USP 600mg Under Fasting ConditionCompletedNCT01827865Phase 1
• Bioequivalence Study of Etodolac Capsules USP 300 mg Under Fasting ConditionCompletedNCT01746719Phase 1
• Bioequivalence Study of Bisoprolol Fumarate Tablet 10 mg Under Fasting ConditionCompletedNCT01741623Phase 1
• Bioequivalence Study of Etodolac Tablet USP 500 mg Under Fasting ConditionCompletedNCT01735370Phase 1
• Bioequivalence Study of Lisinopril Tablets 40 mg Under Fasting ConditionCompletedNCT01735318Phase 1
• Bioequivalence Study of Risperidone Tablet 1 mg Under Fasting ConditionCompletedNCT01722201Phase 1